Ramucirumab (RAM) exposure-response (ER) relationship in RANGE, a randomized phase III trial of docetaxel (DOC) with or without RAM in advanced urothelial carcinoma (UC) patients (pts) who progressed on or after platinum therapy.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.4526
Abstract: 4526Background: RAM+DOC improved PFS & had acceptable safety in UC (Petrylak, et al Lancet, 2017). RAM ER relationships are reported. Methods: Pts received RAM (10 mg/kg) + DOC (75 mg/m2) or placeb... read more here.
Keywords: exposure response; doc; ram exposure; response relationship ... See more keywords
Sequencing of ramucirumab (ram) and immune checkpoint inhibitors (ICIs) in platinum (Pt)-treated real-world patients (pts) with advanced non-small cell lung cancer (aNSCLC).
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.e21209
Abstract: e21209Background: Ram+docetaxel & ICIs are FDA-approved for aNSCLC pts failing Pt therapy. Optimal sequencing of these regimens is unknown. The study objective was to evaluate sequence patterns and... read more here.
Keywords: immune checkpoint; checkpoint inhibitors; ram immune; sequencing ramucirumab ... See more keywords